XSPA - Gingko Bioworks XpresSpa expand COVID surveillance program to include Omicron

XpresSpa Group (XSPA -0.6%), with Ginkgo Bioworks (DNA -0.2%) and the CDC, will expand an airport COVID-19 surveillance program to include the new Omicron variant. XpresSpa's XpresCheck subsidiary expanded its COVID-19 biosurveillance program on Sunday to test passengers entering the United States from Southern Africa. The program has two types of tests. One is a PCR test done on a pooled sample collected at the airport on arrival. The second is an at-home specimen collection kit that is mailed back three to five days after arrival into the U.S. Ginkgo's biosecurity and public health effort, Concentric by Ginkgo, is managing the testing program. Read about XpresSpa's Q3 2021 earnings.

For further details see:

Gingko Bioworks, XpresSpa expand COVID surveillance program to include Omicron